Discussion
There are reports that secretin stimulates insulin secretion without affecting blood levels of glucose and glucagon, in man (Boyns et al., 1967 , Pfeiffer et al., 1973 . It has been reported that secretin acts on the Pancreatic Polypeptide (PP) cell in stimulating PP secretion by a non-vagal cholineigic mechanism (Glaser et al., 1980) , but the mechanism by which it acts on the pancreatic B cell still remains to be clarified. In the present study it was shown that secretin stimulated insulin secretion without the mediation of the vagus nerve and cholinergic nerve. Deckert et al. indicated that secretinstimulated insulin secretion was not inhibited by adrenaline and that the sympathetic nerve was not involved (Deckert et al., 1970) . It is therefore conceivable that rather than act through the mediation of nerves secretin acts directly on the B cell, and the presence of a different receptor from glucoreceptor is suggested in relation to this action. The secretin preparation used in the present study was Secrepan (Eisai Co. Tokyo, Japan). Secrepan and GIH secretin both stimulated IRI secretion similarly. Since one unit of Screpan corresponds to 1/4 GIH clinical unit (Tachibana et al., 1979) , the former can be considered to be a secretin preparation of high purity.
On the other hand, CCK-8 and Caerulein, potent stimulants of pancreatic exocrine secretion, are also known to stimulate pancreatic endocrine secretion. There are reports that these agents strongly stimulate insulin secretion in rats (Ohneda et al., 1978 , Ri et al., 1982 . However, as noted in the present study, neither CCK-8 nor Caerulein stimulated insulin secretion, in man at submaximal or maximal exocrine pancreas stimulating dose levels. This suggests that there may exist receptors of differing sensitivity, or that these agents may have certain specificities in different species.
The insulin response to 75-gm GTT along with a significant positive correlation between CPR content in 24-hour urine (Sako et al., 1984 , Matsuda et al., 1984 , and which is said to clearly reflect the amount of endogenous insulin, and insulin response to a secretin load in NIDDM patients indicates that the insulin response to the secretin load in NIDDM patients can be a reliable measure of insulin secretion, in diabetics. The insulin response was depressed in a stepwise fashion in the order of insulin, oral SU and diet after a secretin load. This suggests that the insulin response to these tests can be used as a useful guide for the determination of an appropriate therapy for patients with diabetes mellitus, and can be used as a simpler test than conventional methods (75-gm GTT and iv GTT).
We also found (data not shown) that the insulin response to a secretin load was not affected by fasting blood levels of glucose and that the secretin load elicited few if any side effects. The secretin load should therefore gain increasing importance as a clinical test. 
Conclusions

